ArticleDrug design, development and therapy2021

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways.

Xuedong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.